Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
This invention relates to methods of using genotyping to select patients for treatment with compounds capable of elevating ketone body concentrations in amounts effective to treat reduced neuronal metabolism associated with reduced neuronal metabolism, for example Alzheimer's disease.
1. A method of treatment for Alzheimer's disease, comprising the steps of:
a. selecting a patient having, or at risk of Alzheimer's disease;
b. determining in the patient the presence of at least one of the specific genotypes selected from the group consisting of:
i. heterozygosity for A/C of Apolipoprotein E (ApoE) rs405509 at relevant portion shown by SEQ ID NO:21,
ii. heterozygosity for G/A of Butyrylcholine esterase (BUCHE) rs1803274 at relevant portion shown by SEQ ID NO:18,
iii. homozygosity for adenine of Insulin-like Growth Factor Receptor Precursor (IGF1R) rs2229765 at relevant portion shown by SEQ ID NO:6,
iv. homozygosity for thymine of Interleukin-1 beta (IL1B) rs1143627 at relevant portion shown by SEQ ID NO:9,
v. homozygosity for cytosine of IL1B rs16944 at relevant portion shown by SEQ ID NO:10,
vi. homozygosity for cytosine of Low-density Lipoprotein Receptor (LDLR) rs2738447 at relevant portion shown by SEQ ID NO:24,
vii. homozygosity for guanine of LDLR rs7259278 at relevant portion shown by SEQ ID NO:25, and
viii. homozygosity for cytosine of LDLR rs1799898 at relevant portion shown by SEQ ID NO:15; and
c. administering to the patient having at least one of the specific genotypes in (b), a composition comprising an effective amount of a composition comprising medium chain triglycerides (MCT) of the formula:
wherein the R 1 , R 2 , and R 3 esterified to the glycerol backbone are each independently fatty acids having 5-12 carbon chains.
2. The method of claim 1 , wherein the method further comprises testing the patient for absence of ApoE4 genotype.
3. The method of claim 1 , wherein the composition is formulated for oral administration and further comprises glucose.
4. The method of claim 1 , wherein the composition is administered in an amount effective to raise the blood level of D-beta-hydroxybutyrate in the patient from about 0.1 mM to about 50 mM.
5. The method of claim 1 , wherein the composition is administered in an amount effective to raise the blood level of D-beta-hydroxybutyrate in the patient from about 0.2 mM to about 5 mM.
6. The method of claim 1 wherein the composition is administered at a dose of about 0.05 g/kg/day to about 10 g/kg/day.